Silver Sol is patented, and scientifically shown to be different!"Silver Sol is simply superfine silver particles dispersed in deionized water. The term "Sol" is a chemical designation of a pure mineral, such as metallic silver, permanently suspended in water where the mineral's charge is transferred to the entire body of water. Silver Sol technology includes advanced scientific research and new product development utilizing its anti-bacterial, anti-viral, and anti-fungal properties." Dr. Gordon Pederson
Silver Sol Technology®, the only active ingredient in DFH Silvercillin, is a recently developed technology (US Patent issued Nov. 14, 2006) with emerging scientific studies and applications. It can be taken orally or applied topically and has been tested to be effective against a wide range of bacteria, fungi, and viruses with outstanding results.
Here's a written quote from General P.K. Carlton, M.D. and the Director of Integrative Centre for Homeland Security: "I would like to bring to your attention a resource that I feel can be utilized in the area of bio-defense from bio-terrorism to infectious diseases such as SARS. The antimicrobial Silver Sol Technology has undergone rigorous testing and has been found to kill anthrax, bubonic plague, hospital Staph and SARS. It is the first new antimicrobial for the hospital in many years. In addition, the product is non-toxic to humans, EPA approved for hospital Staph and bubonic plague and currently awaiting section-18 approval for anthrax. In short, we currently do not have anything with such a wide spectrum of efficacy in our inventory. As such, I recommend that the antimicrobial be evaluated for addition to the national push-back stock pile."
A recent article entitled "Silver Sol and the Successful Treatment of Hospital Acquired MRSA in Human Subjects with Serious Ongoing Infection" documented the treatment of 308 elderly patients with hospital acquired drug-resistant infections. The results included an average wound closure time of 5 weeks on HA-MRSA wounds (hospital acquired, drug-resistant infections) previously ongoing for 1 year.
|
